Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (131-140 of 346) with videos related to

Pageof 35
Sort By:
Leukemia|October 19, 2022
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysisNicholas J Short, Chenqi Fu, Donald A Berry, et al.
JAMA Oncology|October 8, 2020
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysisNicholas J Short, Shouhao Zhou, Chenqi Fu, et al.
American Journal of Hematology|October 10, 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsIman Abou Dalle, Hagop M Kantarjian, Nicholas J Short, et al.
Haematologica|May 23, 2024
Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemiaAmber Gibson, Cesar Nunez, Lindsay Robusto, et al.
Haematologica|March 26, 2026
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemiaDaniel Nguyen, Elias Jabbour, Hagop M Kantarjian, et al.
British Journal of Haematology|April 11, 2024
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expressionWei-Ying Jen, Koji Sasaki, Sanam Loghavi, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>-4</sup> and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood Advances|February 6, 2026
Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow CytometryShaoying Li, Nicholas J Short, Wei Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2022
Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results AnalysisAmy M Berkman, Clark R Andersen, Branko Cuglievan, et al.
Pageof 35

Showing results (131-140 of 346) with videos related to

Sort By:
Pageof 35
Leukemia|October 19, 2022
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysisNicholas J Short, Chenqi Fu, Donald A Berry, et al.
JAMA Oncology|October 8, 2020
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysisNicholas J Short, Shouhao Zhou, Chenqi Fu, et al.
American Journal of Hematology|October 10, 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsIman Abou Dalle, Hagop M Kantarjian, Nicholas J Short, et al.
Haematologica|May 23, 2024
Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemiaAmber Gibson, Cesar Nunez, Lindsay Robusto, et al.
Haematologica|March 26, 2026
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemiaDaniel Nguyen, Elias Jabbour, Hagop M Kantarjian, et al.
British Journal of Haematology|April 11, 2024
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expressionWei-Ying Jen, Koji Sasaki, Sanam Loghavi, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
American Journal of Hematology|June 17, 2022
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>-4</sup> and higherElias J Jabbour, Nicholas J Short, Nitin Jain, et al.
Blood Advances|February 6, 2026
Prospective Feasibility Study of Peripheral Blood for MRD Detection in Acute Myeloid Leukemia by Flow CytometryShaoying Li, Nicholas J Short, Wei Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2022
Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results AnalysisAmy M Berkman, Clark R Andersen, Branko Cuglievan, et al.
Pageof 35